OLARTERAISBECK
OLARTE RAISBECK MOURF:.. ..

SUPEINrENDENCIA DL INDUSTRIA V COMLRCIO IIIIIHIIIIIIIIIIIIIIUIIIIIIIIIIIIII No. 07-070604- -00005-0000

Thidstirtt Fcha: 2010-11-12 16:53:04 Dsp. 2020 DIR.NUEVASCR r, ii PAIENTEIYU Lye: 379 FASENACIONALII
SUP ERI N I N 0 E N C I A Act. 329 CIOINFORMACION Folios: 15

FORMULARIO (JNICO DE CORRECC]ÔNES Y MODIFICACEONES

P2007 0001231 -.---,----------__ SOLICITUDDE:
Correccion de Error Material. I I Modificaclon a una Soilcituci.

0 Nombre:Sentinella Pharmaceuticals, Inc EDENTIFICACIÔN
SOLICITANTE Direcci6n:47 Hulfish Street, Suite 310 C.C. NIT I I
(71) Princeton NJ 08542 USA
Nacionalldad o Domicilio: Estadounidense C.E. [jOtro
Lugar de Constitución:Estados Unidos de
America Cual

TelØfono: Fax:I Nümero____________

...- _.

IDENTIFICACIÔN
Nombre: CARLOS R. OLARTE
NIT

REPRESENTANTE Dlrección: Diagonal 34 No. 5-28 Bogota

CE. Otro 0 APODERADO i_________________________________ [_J TelØfono: 601-7700 Fax: 601-7799 Cual___ E-mail: Nümero79.782.747 Eta.

TP 74.295 (Ii) -------------

NCimero de expediente:
07-070.604

(,3) Descripción de Ia corrección o modificación solicitada Me permito presentar la

ceslón de derechos del solicitante., NAICONS S.c.a.ri. cedlendo sus derechos a NextfteraBiociences s.r.I. esta cede a suvezSENTINELLA PHARMACEUTICALS,-
INC,

,,.------..---..-.-------------.--.--.---.--.-----.,-.-

(3) Comprobante de pago No. 10-96.001 Fecha 11 Noviembre 2010

H (3).Anexos
IX 1 Comprobante de pago de la
Copia autØntica del Poder Documento original que soporta la cesión de
derechos.

Documento que. acredita la existencia Y representación legal de [as partes, cuando

-- -- Z-OO-00 1.
..

--

OLARTERAISBECK
OLARTE RA1S13ECK MOURE 8c CASTRO LTi,A.

Power of Attorney

The undersigned,
1

domiciled in
47 Hulfish Street, Suite 310 -

Poder

El suscrito,
Pharmaceuticals’ Xnc.
domiciliado on
Princeton, NJ 08542, USA

by means ofthese presents hereby grants to Carlos IL Olarte and/or J. Ian Raisbeck and/or Juan Guillernio Moure and/or Natalia

Castro full and sufficient Power of Attorney to file, prosecute, obtain, defend and enforce any and all ofthe company’s Patents for Inventions, Utility Models, Layout-Designs (topographies) of Integrated Circuits, Industrial Designs, Trademarks, Advertising Slogans, Trade Names, Commercial Emblems, Geographical Indications, Protection of Trade Secrets, Obtainer’s Certificates, Copyrights, Registration of Domain Names, Health Registrations, or any other intellectual property right in the Republic of Colombia, to which end it empowers them to take all steps necessary before any administrative or judicial authority of any class for the objects stated, to file petitions, recourses, replies and oppositions, pay taxes and annuities, request testimonies, receive documents and securities, abandon applications, collect refunds, desist, settle, conciliate or negotiate. Sufficient power is hereby granted to receive notifications on behalf of the Company, to confer powers on those who are to represent the company judicially and extrajudicially, to answer in court in the matter of all claims and demands that may be presented in connection with the objects stated, giving them likewise power to substitute these presents and revoke such substitutions.

4,
’?(J. lan Raisbeck
Juan Cuillerrno Moure
V Natalia Castro

der Agudelo
Ca i l3arbastcfano
Angola Correa
Erika Ricd
Curios A. Parra
Andris Alvarado
Gina Arias

Juan Felipe Acosta
Andr?.’s Rincón
Grace Garcia
Mariana Franco

por medio del presente otorga a Carlos it Olarte y/o J. Ian Raisbeck y/o Juan Guillermo Moure y/o Natalia Castro poder amplio y suficiente para presentar, tramitar, obtener, defender y hacer respetar todas y cualquiera do las Patentes de Invención, Modelos do Utilidad, Esquemas de Trazados do Circuitos Integrados, Diseilos Industriales, Marcas, Lemas Comerciales, Nombres Comerciales, Enseas Comerciales, Denominaciones de Origen, Protección do Secretos Empresariales, Certificados do Obtentor, Dereehos de Autor, Registro do Nombres de Dominio, Registros Sanitarios, o cualquier otro bien do propiedad intelectual de la compafila en La RcpbIica de Colombia, a cuyo efecto los faculta para dar todos los pasos necesarios ante cualquier autoridad administrativa o judicial de cualquier jerarqula pam cumplir con to encornendado, elevar solicitudes, recursos, respuestas y oposiciones, pagar impuestos y anualidades, solicitar testinionios, recibir docurnentos y valores, desistir, transigir, y percibir. Se concede poder bastante para recibir notificaciones a nombre de la compafila, otorgar poderes a quienes vayan a representar a la compaflia judicial y extrajudicialmente, responder en juicio a todas las reclamaciones o demandas que por motivo.de lo encomendado se presentaren, dÆndoles asimismo facultad para sustituir el presente y revocar dichas sustituciones.

Signature/Firma: J4ZpAt

Date/Fecha: 1J-, 2-0 tO

City,Country/Ciudad,Pais:

- USA-

AUTE Diagonal 34 N° 5 - 28, Bogoti D.C.,Colombia
EL A71601-7799, fficeo1arteraisbeck,com, www.olareraisbeck.com

Of Coutmel
Guillermo Chahin
Graciela Mob
Jacqueline Chaparru
Cruz E. do Moncalcano

- v -

FroJuccl6n oicI Je un Jacumento cuoogn en lngl6s

Se/to en las certficaciones notariales y a/final de la hoja defirmas del documento adjunto: "Nancy J. Thornton. Notario Püblico de New Jersey. Mi non-ibramiento vence el 11
de agosto de 2011"

Texto antes de la apostilla italiana:
"Dr. Paolo Sala - Fr. Vittorio Meda. Yo, el suscrito Doctor Paolo Sala, Notario Püblico en ejercicio en Milano, Italia, certifico por el presente que este documento fue firmado frente a ml por el seæor Stefano Donadio, riacido en Salerno el 4 de enero dc 1956, en nombre de "NEW ANTI-INFECTIVES CONSORTIUM

(NAICONS S.c.a.r.L)", ubicada en Via Fantoli Gaudenzio n. 16/15, Italia, y la seæora Daniela Jabes, nacida en el 14 de enero de 1953, en nombre de "Nexthera Biosciences S.R.L.", ubicada en Corso Indipendenza, n. 14, Milan, Italia, a quienes conozco y quienes son las personas que firmaron el anterior documento
y quienes tienen capacidad legal para. hacerlo. Milan, 4 de junio de 2010".

(Firmado)
Hay un sello notarial.

Hay una apostilla italiana certificada en Milan el 10 dejulio de 2010.

Apostilla adjunta:

Induallr JORGE L SJER
Ucbd 3’ -1993 ml,btj j.

OLIARTERAISBECK j coorte
Oz..ARTERA1SBECKMOUn&CASTROLTDA(_) Juan 0
Natalia Castro

Agudelo
Ca5 tefano
laCorrea

ASSIGNMENT CESIONRj

los A. Pares
An Ø Alvarado

NAJCONS s.c.a.rJ. harias
VIA GAUDENZIO FANTOLJ 16/15 Juan Felipe Acosta
20138 MILANO Andrea Rincón
ITALY Aria Fernandez de Soto
OfCounsel
Guillermo Chahin

by means of this document and in consideration por medio de la presente y a cambio del pago de GeM Melo
of the payment by the Assignee to the Assignor una contraprestación económica, cedo (cedemos)Jacqueline Chaparro
of a good and valuable consideration, assign(s) to a

Cruz E. de Moacaleano

NexTbera Biosciences S.r.L

organized under the laws of Italy Domiciled in organizada bajo las leycs de Italy domiciliada en
Corso Indipendeuza, 14 Corso Indipendenza, 14
20129 Milano, Italy IT 20129 Milano, Italy IT

all my (our) rights, title and interest in and to my
(our) invention for a new and useful
improvement entitled and as fully set forth and
described in:

07-076.577 - 07-070604
Antibiotic 107891, its Factors Al And A2, Pharmaceutically Acceptable Salts And Compositions, And Use Thereof

todos mis (nuestros) derechos, titulo e interØs sobre ml (nuestra) invención tal como se describe
on

07-076.577 - 07.-070604
Antibiotic 107891, Its Factors Al And A2, Pharmaceutically
Acceptable Salts And Compositions, And Use Thereof

likewise asi mismo
NexTbera Biosciences S.H. NeiThera Biosciences S.r.l.

. by means of this document and in consideration por medio de la presente y a cambio del pago de
of the payment by the Assignee to the Assignor una contraprestación económica, cedo (cedemos)
of a good and valuable consideration, assign(s) to a

Sentinella Pharmaceuticals, Inc.

organized under the laws of Delaware
Domiciled in
47 Hulfisli Street, Suite 310
Princeton, NJ 08542, USA

,40 all my (our) rights, title and interest in and to the
invention for a new and useful improvement entitled and as fully set forth and described in:

07-076.577 - 07-070604

Antibiotic 107891, its Factors Al And A2, Pharmaceutically Acceptable Salts And Compositions, And Use Thereof

So far as the Republic ofColombia is concerned.

Place, date

Sentinella P)armaceutica1a Inc.

organizada bajo las leyes de Delaware domiciliada en
47 Hulfish Street, Suite 310 Princeton, NJ 08542, USA

todos mis (nuestros) derechos, tItulo e interØs sobre la invención tal como se describe en

07-076.577 - 07-070604

Antibiotic 107891, Its Factors Al And A2, Pharmaceutically Acceptable Salts And Compositions, And Use Thereof

on lo que concierne a la RepiSblica de Colombia.

Lugar, fecha

Diagonal 34 No 5 -28, Bogota D.C., Colombia - Tel + 57 1601-7700, Fax + 57 1601-7799, office(2Iarteraisbeck.com, www.olarteraisbeck.com

OLARTERAISBECK
OLAnTE RAISBECK MOURE 8 CASTRO LTDA.

Aico
Stefano Donadio -Director

’Laa??
/-) -,

- - - NexThera Bioscienc s S.rJ.

Daniela Jabes -Director

Sentinella Pharnia

Lorenzo Pellegrini Vice Pre dent

I

NAICONS a r 1 Stefano Donadia Director Stefano Donadio. -Director

NexThera Biosciences.r.1. -
Daniela Jabes -Director

Sentinella PharmaceuIa&r’
Lorenzo Pellegrini Vice Presiden

Pigina 2 de 4

Nancyi. Thornton
Notary PubilcofNew Jersey
My Commission ExpiresAugust 1112011

10

22.9

Dr. PAOLO SALA Dr. VITrORIO MEDA 1A
NOTAI ASSOCIAT1
MILANO.Vla COMAIIII 14 T1 02.730677 r.o
1Mf ØWflI 11 t in MMAK

I undersigned Dott. PAOLO SALh a Notary Public in Milan, Italy, do he-reby certify that this document was signed in front of me by Mr STEA-NO DONADIO born in Salerno 4t h January 1956, on behalf of ANEW ANTI-INFECTIVES CONSORTIUM (NAICONS S.0 a r. 1.).", Via Fantoli GaudenziO n
16/15, Milan (Italy), and Mrs DNIEL JABES born in Milan January
14th, 1953, on behalf of NZXTHERA BIOSCIENCES S.R.L.",, Corso mdi-pendenza n. 14, Milan (Italy), to me known, to me to be the persons who executed that foregoing document, and who have legal capacity to
execute it.

Milan, Italy, June 4th, 2016

(Cverition on

JLL
d La Hays du 5 octobr 19i)
ITALXA :tT

11 nresenrattci pubblico p .
2 e o rrotrjtto da..,..L ....

3. anie in Qu.1IIra dL.. kQ.Q..............

4 e:;ek_,jjajI d,11 contras rIo/t10

ry.
At t e s t a t o

5 1--1110................................... 6.. i1..1...
7 ti L ’ui:io del pubhlico rninter
S turn 3eL.

tuxwro -F I

10. Firma

1-1

ILPROCUATOPJDRnUC (dogi. Giowm, a

..’ V

* 4W
T

Dott PAOLO SALA - Dott. VITTORIO MEDA
NOTN ASSOCIATI
20129 MU.ANO -Via Ceradlnl, 14
Ar Tel. 02.7384154- 02.730677 r.a. -Fax 02.7490884
20059 VIMERCATE -Via Cremagnanl, 11
Tel. 039.6851191 -Fax 039.863409

E-mail: psala@notariato.ft
E-mail: vmedanotariatoJt

Milano, 4 giugno 2010

CERTIFICATO NOTAR1LE

Certifico lo sottoscritto dr. PAOLO SALA Notaio in Milano, iscritto al Colteglo Notarile di Milano, chØ la società "NEW ANTI-INFEGTIVES CONSORTIUM", società consorti-le a responsabllità timitata con sede in Milano, Via Fantôli Gaudenzio n. 16/15, iscrit-ta ÆHaCamera di Commercio di Milano al n. 1827845 R.E.A., numero di iscrizione at Registro della Impress di Milano e Codice Fiscale 05511330960, Łufla società le-galmente esistente secondo le leggi Italians, e che la Signora Jabes Danieta nata a Milano 14 gennaio 1953, Ł Presidentsa Amministratore delegato, con i poteri per rappresentare legalmente la società.e per impegnarta, a iisuttanza del Verbal! del Consiglio di AmminIstrazione in data 23 aprile 2009 e 3 giugno 2009, e deIl’Assem-blea in data 10 giugno2009.
Infede.

APOSm.L.E
flV6flOn.de I’a Hay du 5 óCwbn 19
ITALIA

praw-Ift atto pubbco (7 2. e stto sottos’ccitto cia.....[

8. agente in qualirâ

,4. e sepato dal con egno./tinibro di..
.... Ir!-.1................

. ...

Attestato

5. a Miktr,o...................................6. ii.......-2ffl
7 dafl’ufficd nubblico minister
sotto il naunero.............. SS?’ ’1011

1

Industria y Comercio
SUPERINTENDENCIA

DIVISION DE NUEVAS CREACIONES

RADICACION EXPEDIENTE No. 07-70604

EL EXTRACTO DE LA PRESENTE SOLICITUD DE PATENTE DE INVENCION

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No 587 DE

FECHA 18 DE ENERO DE 2008 EL TERMINO HABJL SEIMLADO POR LA LEY

EXPIRA EL 16 DE ABRIL DE 2008

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir do la fecha de publicaciôn en la gaceta do Propiedad Industrial, deberÆ solicitar y cancelar & examen de patentabilidaci so pena do quo la solicitud caiga an abandono, do acuerdo con lo establecido en el Articulo 44 do (a DecisiOn 466/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____ NO X

*4

Ll

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau I IN 1131 11 111111111111111111111111111111111111111111111111111111111111111111111

(43) International Publication Date (10) International Publication Number
17 February 2005 (17.02.2005) PCT WO 2005/014628 Al

(51) International Patent Classification7: C07K 14/195,
2/00,4/04, Cl2P 1/06, A6IK 38/02, A61P 31/04, A23K
1/17/I (Cl2P 1/06, C12R 1:01)

(21) International Application Number:
PCT1BP2004/007658

(22) International Filing Date: 12 July 2004(l07.2Q.

(25) Filing Language: English

(26) Publication Language; English

(30) Priority Data:
03016306.703 ’.2093 £1’

(71) Applicant (for all designated States except US): VI-CURON PHARMACEUTICALS INC. WSIUSI; 455 South Guiph Road, Suite 305, King of Prussia, PA 19406 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only); LAZZAEJNI, Ameriga [fl/iT]; Via 29 Maggio, 5, 1-20025 Legnano (IT). GASTALDO, Luciano [IT/IT]; Via San Martino, 7, 1-20010 Pogliano Milanese (ti’). CANDIANI, Glaupaolo

[IT/IT]; Via Rdllini, 2/C, 1-20064 Gorgonzola (IT), Cl-CILLATO, Isniaela [ITfIT]; Via Orazio, 7,1-21052 Baste Arsizio (IT). LOS1 Danlele [IT/IT]; Via Came, 28/B, 1-22069 Rovellasca (IT). MARINELLI, Flavia [IT/IT]; Via Rubens, 25, 1-20148 Milano (IT). SELVA, Enrico [iT/IT]; Via Di Vittorio, 23,1-27027 Gropello Cafroi M. PARENTI, Franca [IT/II]; Via B. Cellini, 24, 1-20020 Lainate (IT).

(74). Agents: SOARBI, Renato at al.; Ing. A. Giambrocono & C. S.r.L, Via Rosolino Pilo, 19/B, 1-20129 Milano (IT).

(81), Designated States (unless otherwise Indicated, for every kind of national protection available); AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, EW, BY, liZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, BE, EG, ES, Fr, GB, GD, GE, GI-T, GM, HR, 1115, 10, IL, IN, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, IT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, P0,
PH, PL, PT, RO, RU, SC, SD, SE, SO, SK, SL, SY, TJ, TM,
TN, TR, TI’, TZ, UA, 150, US, UZ, VC, VN, YU, ZA, ZM,

(84) Designated States (unless otherwise indicated, for every
kind ofregional protection available): ARIPO (BW, OH,

[continued on next page]

(54) Title: ANTIBIOTIC 107891, ITS FACTORS Al AND A2, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPO-SITIONS, AND USE THEREOF.

Itt mhz

(57) Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which
is produced by fermentation ofMicrobispora sp. ATCC PTA-5024, the phannaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which Is a complex ’’I comprising two Factors, denominated Factors Al and AZ has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics ofthe antibiotics ofthe lantibiotics group. Antibiotic 107891 and its Factors Al and A2 show a good antibacterial activity against Gram-positive bacteria including methidilin resistant and van comycin resistant strains, and is active also against some Gram-negative bacteria suchas M. catharralis, Neisseria species and H. influenzaeand Mycobacteria.

H T

WO 20051014628 PCTIEP2004/007658
- 14-

fermentation broth of the producing microorganism is conducted according to known per Be techniques which include extraction with solvents, precipitation by adding non-solvents or by changing the pH of th6 solution, by partition chromatography,
5 reverse phase partition’ chromatography, ion exchange chromatography, molecular exclusion chromatography and the like or a combination of two or more of said techniques. A procedure for recovering the compounds of the invention from the filtered fermentation broth includes extraction of
10 antibiotic 10791 with water-immiscible organic solvents, followed by precipitation from the concentrated extracts, possibly by adding,a precipitating agent.
Also in this case, the term "water-immiscible solvent" as
used in this application, is intended to have the meaning
15 currently given in the art to said term and refers to
solvents at the conditions of use, are slightly miscible
or practically immiscible with water in a reasonably wide concentration range, suitable for the intended use. - Examples of water-immiscible organic solvents that can be
20 used in the extraction of the compounds of the invention from
H the fermentation broth are:
alkanols of at least four carbon atoms which may be linear, branched or cyclic such as n-butanol, 1-pentanol, 2-pentanol, 3-pentanol, 1-hexanol, 2-’hexanol, 3-hexanol, 3,3-d–methyl--l-
25 butanol, :4-methyl-1--pentaol, 3-methyl-1-pentanol, 2,2-
dimethyl-3-pefltanol, 2, 4-dimethyl-3-pentanol, 4, 4-dimethyl-2-pentanol, 5-methyl-2-hexariol, 1-heptanol, 2-heptanol, 5-methyl-1-hexanol, 2-ethyl-l-hexanol, 2-methyl-3-hexanol, 1-. octanol, 2-octanol, cyclopentanol, 2-cyclopentylethanol, 3-
30 cyclopenthyl-1--propanol, cycloheçanol, cycloheptanol,
cyclooctanol, 2,3-dimethyl-cyclohexanol,4 -ethylcyclohexanol, cyclooctylrttethanol,
t 4 -

6-rnethyl-5-hepten-2-01, 1-nionanol, 2-

5

wo
- 13-

ATCC PTA-5024 capable of producing antibiotic 107891
deemed quivalenit to it for the purpose of t is n entio
therefo a within he sccpe cf invention.’
XTRACTI-CN AND P1JR-IF CATION--OF-ANT’ZBIOIU.Iq 1079911
As entioned Tabove; antibiotic 07891. i o nd a
equally distributd bot in trie myceliUni an n the fil
fraction of the f rmentationi broth.

FA

The harvested broth may be pro esqed to, ieparate t
mycelium from the supe?natant of the ferriertatt n brotli a
10 the mycelium may be extrac ed with a water-mi6ci)le solve
to obtain a solution cnta ni g the07$9 ni otic, t
removal of the spent myceli This ycell et c may h
be pro essed separately o in Poo With the upern a
accordi g to th procedu e repor ed a eft r for t
15 superna ant frac ion. When he wat r-mi ci e s ivent in
cause nterfereri as with the operat oris for re o ering t
antibiotic from the mycelium extract,; th wi te r-mis b
solvent may be re

I

moved bv distillation or iftai, be diluted I
water to a non-interferirig concentration’.
20 The term "water-micib e solvent" EZ usrz d in thl
application, is intended to have the mean.ing dur cently yE
in the art of this tarn and refers t o so ye tis that, at ti
conditi ris of use, are miscible wit water i reaso b
wide co centratlo range. xa pies o water misc b a or n1
25 solvent that can be ued n the ext action o t e comp ric
of the invention are: ’Ilower aikanol, 0. alkanal

such a methano, etiano, and p opan 1; phi n 1 (
alkanol such as benzyl alcohol; lower ke o e, e.g. (
ketones such as a atone and at yJ. methyl ke o e; cyc ic etber
30 such as dioxane and tet a ydrofur n; gl co’ls and thei
productp of partial at sri ic tion s ch a3 ethy e a glycol
propylene glycol, and ethylene glycol mono a hl Bther, o a
amides such as dimethyl ormami de and ieth 1 ozna i a; a e i
acid dimeth xide a d a et onitril

35 The i ecovery of the:compound from the supemna a it of th

WO 2005/014628 $T P2 04/0076 8 _58-

chromato raphy, reverse phase partition c r mto r phy, o
exchange chromato raphy, mo ec lar ex lusi n hr m

3

togra y,
and a co ination f two or r of sai techniques

9. A process acc rding to any of claims 6 n 7, herein h
5 isolatio of the antbiotc 107892 is ca?rii d out b
separati g the mycelitim Erom the sup r aian of h
fermentation broth and te m ce ium.is extra t diw h a wa r-
miscible solvent whereb’, ft r the rexao a of he spent
mycelium., a wate -miscible solution. coPt i iiig t e crude
10 antibiotic is ob ained, w Ach can be p o4es e either
separately or in ool with t e filtered er ent ton broth
according to claim 8 to recover the antibiot c 178 1 by means
of a tehnique selected fr in extraction w ti solv n
precipita ion by adding a non s ivent o by cha nin the pF of
15 the solution, absorptioi chrom tour p y, arti I n
chromatography, re ersephas a partiti n throzatog a hy, ion
exchange chromatography and molocialz r xclusi n
chromatography, Or a combination of tw’8 or OrB of said techniques.

20 10. A process as in claizn 9 whezpbythe c;oncentrat on of the
water-miscible sol ent i6 the myceli extract a redu d
before it is proces edto r: ecover the antibiotic: Ithe a rom.
11. A process according to claim B whØr b the filtered
fermentaton broth is cnta ted with an. b opt o res,
25 preferabi a polysiyrene, a mixed pol styr ne div n lbenz ar IS
or a poly amide resin, ancsad resin I elute it I p01 3.1
water-miscible solent or a nixture th’ereo wdth watex,
whereby a solution containing t ie crud ant boiic 1 7981 Is
obtained.

30 12. A process as in an of claims and 10 wk e ein the
mycelium is extra ted iith il C1 -C3 aikanc l, r fera ly
methanol, and the myce1um extract s:,cont ac?ec ith a
absorption resin,p eferably. olysty ene as n n elu e
therefrom with a p lar water -miscible solv ntr a mixt r
35 thereof wj th water, wherby a solution corit i iig t e cr d
antibiotic 107891 is obtaiied.

- I-
WO 2005/014628 PCT/1tP2004/007658 7

- 59-

13. A process as in any of claims 8, 9, 10 and.12, wherein the
solutions containing the crude antibiotic 107891 are pooled
and processed for further purification of said antibiotic

107891.

5 14. A process as in any of claims 11, 12 and 13, wherein the
solution containing the crude antibiotic 107981 is concentrated and then freeze-dried to yield a crude antibiotic 107891 solid product.
15. A process as in any of claims 11 and 12, wherein the
10 absorption resins containing the absorbed antibiotic are pooled and their mixture is eluted with a polar, water-
. . miscible solvent or a mixture thereof with water.
16. A process according to any of claims 6 to 15 wherein the
antibiotic 107981 is purified by means of a chromatographic
15 procedure, preferably by preparative MPLC or medium pressure
chromatography.
17. A process according to any claims 6 to 16, wherein Factor
Al and Factor A2 are separated by preparative HPLC from the purifiód antibiotic 107891.
20 18. A pharmaceutical composition comprising an antibiotic selected from antibiotic 107891, its Factor Al, its Factor A2 according to any of claims 1 to 5 and a mixture of said Factors in any proportion or a pharmaceutically acceptable salt thereof with an acid.
25 19. A pharmaceutical composition according to claim 18, comprising a pharmaceutically acceptable carrier.
20 The antibiotic 107891, its Factor Al, its Factor A2,
according to any of claims 1 to 5 or a mixture of said Factors
in any proportion or a pharmaceutically acceptable salt
30 thereof with an acid for use as a medicament.
21. Use of antibiotic 107891, its Factor Al,. its Factor A2,
according to any of claims 1 to 5, or a. mixture of said
Factors in any proportion or a pharmaceutically acceptable salt thereof with an acid for the manufacthre of a medicament
35 for the treatment or prevention of bacterial infections.

Wł242R .-

22. Use’ Of the an4ibt4 aco tact
co-rd’ing I 45 oIct f ada H
in any proportiri land a 0 aa thØr o it n ac d\’
aflimal g owth prompter.

5 2-3. Abi 109,14ally puz"t Oult ra of tttel5ta ri c*por H
ATCC PTA 5024,- or vrint o mutaut thee ’f- trthg..
ab.l.ity 0 poduc th t’ c af 4P’Ja$n. -4’igtjv e.
under s bmergsd’aercibi 4ition.s th ence Ck
assixniJ.a le souces11 of -aon itro-1ri x -o g x c salts
10

1.

H

H

H:..

10,

SUPERINTENDENCIADE INDUSTRLA Y COMERCIO DRECC16N DE NUEVAS CREACIONES

2020

Bogota, D.C., 8 de marzo de 2011

Abogado
I CARLOS R. OLARTE

ASUNTO Radicación TrÆmite
Evento
ActuaciOn
Oficio
Folios

Patente de lnvenciôn II

Via Nacional 0

Via POT (fase nacional)

No. Sol. Internacional
Fecha de Presentaciôn Internal.

0770604
011
379

29

Patente de Modelo de Utilidad 0

Cap. I M Cap. II 0

PCT1US20051004843
19-01-2005

Como resuttado del examen de fonda, realizado con fundamento en el articulo 45 de (a Decision 486 de la Comisiónde (a Comunidad Andina, se le comunica:

1. Documentos estudiados

DescripciOn: Folios: 93 a 157 (coma se radicó inicialmente)

Reivindicaciones: Folios 158 a 170 (coma se radicO inicialmente)

Dibujos: Folios 172 a 189 corno se radicO inicialmente

Prioridad: Fecha: 12-01-2005; pals y nümero: US 11/035.296.

2. ObJeto de fa lnvención

Titulo de la invenciOn: "ANTIBIOTICO 107891, SUS FACTORES Al Y A2, SALES V COMPOSICIONES FARMACEUTICAMENTE ACEPTABLES, Y USO DE LOS M.ISMOS."

Problema TØcnico Planteado: la necesidad de proveer nuevos antibiOticos.

SoluciOn: extracciOny purificaciôn del complejo antibiOtico 107891:

reivindicaciones no son patentables.

S. Determinación del Estado de la TØcnica

La fecha que Se ha tenido en cuenta para determinar et Estado de la TØcnica es:

Fecha de presentaciôn de la soilcitud prioritaria 12-01-2005

Teniendo en cuenta la fecha indicada se realizó la büsqueda en el estado de la tØcnica de documentos relacionados con la soilcitud encontrÆndose los siguientes documentos mÆsrelevantes:

No Documento Titulo Fechade
prioridad
ANTIBIOTIC 10789, ITS FACTORS Al AND

Dl W02005/014628* A2, PHARMACEUTICALLY ACCEPTABLE 18-07-2003 SALTS AND COMPOSITIONS, AN USE

.THEREOF

acuerdo con of numeral 5.2.2 de (a Circular Unica, cualquier solidtud internacional que designe a Colombia tendrÆ, desdela fecha de presentaciôn internacional, los efectos de una presentación nacional regular en Colombia.

Dl enseæa el aislamiento de antibióticos a partir de Microbiospora coral//na, y el proceso para producir dichos antibiôticos, al igual que las condiciones de fermentaciôn (pag. 13 I Ineas 5-19)

7, AnÆlisisde Patentabilidad (Art 14 D486)

Novedad (Art 16 D486)

La reivindicaciôn 16 reclama un procedimiento para producir antibiôtico 107891 y
sus Factores Al y A2 y las sales de los mimos.

La reivindicacióri 29 solicita una composición farmacØutica que comprende un antibiôtico seleccionado del antibiótico 107891, Factor Al o Factor A2 del mismo.

La reivindicaciôn 34 rectama un cultivo biolOgicamente puro de (a cepa
Microbiospora sp. ATCC PTA 5024.

AnÆlisisde las diferencias con respecto al estado de la tecnica;

Caracteristicas esenclales de la Solicltud 02
W02005/014628

Un procedimiento para producir antibiótico Un procedimiento pars producir.
107891 sus Factores Al A2 las sales de antibiôtico 107891 sus Factores Al
los mismo s con Æcidos que comprende las A2 las sales de los mismo s con
etapas do: Æcidos quo comprendelas etapas de:

Cultivar Microbiospora sp. ATCC PTA-5024 a SI
una de sus variantes o mutantes, manteniertdo Cultivar Microbiospora sp. ATCC PTA-
la capacidad do producir dicho antibiOtico, en 5024 o una do sus variantes a
condiciones aerObicas, en un media acuoso mutantes, manteniendo Is capacidad
en nutrientes. de producir dicho antibiôtico, en
condiciones aeróbicas, en un medlo

Exp. 2007 70604

acuoso rico en nutrientes.
(Reiv._6)
SI

Aislar el antibiOtico res9ltante del micelio Y/O Aislar el antibiótioo resultante del
micelio yb del caldo de fementaciôn del caiclo de fementaciôn filtrado filtrado
(Rely._6)
St
Purificar el antibioco 107891 aislado Purificar el antibiOtico 107891 aislado
(Rely._6)
SI

Una composición farmacØutica que
Una composiciôn farmacØutica qua comprende comprende una antibiôtico
una antibiOticc seleccionado del antibiôtico seleccionado del antiblótico 107891,
107891, FactorAl del antibiôtico 107891, Factor Factor Al del antiblôtico 107891,
A2 del antibiOtico 107891 una mezcla do Factor A2 del antiblOtico 107891 una
dichos factores en cualquier proporclOn. mazda do dichos factores en cualquier
proporcion
(Rely._18)
SI

Un cultivo biológicamente puro do la cepa

Un cultivo biológicamente puro de la

Microbiospora sp. ATCC PTA-5024 cepa Microbiospota sp ATCC PTA-5024
(Relv.23)

En concordancia con lo anterior, se puede evidenciar que el procedimiento, la composiciOn y el cultivo de la cepa Microbispora sp. Ya se habla divulgado en Dl, en consecuencia, las reivindicaclones 16 a 30 y 34 carecen de novedad.

En cumplimiento del articulo 45 de la DecisiOn 486 do la Comisión de la Comunidad Andina, se le indica que debe där respuesta dentro del tØrmino de sesenta dias contados a partir de Ia fecha de notificaciOn de la presente comunicaciOn. En caso do no dar respuesta at presente requerimiento, 0 Sj a pesar do. la respuesta subsistieran los impedimentos para Ia concesiOn, se denegara la patente.

Notifiquese el presente oflcio conforme a Ia dispuesto en el numeral 5.2, literal e), del capItulo quinto del. titulo primero de la Circular Unica NO 10 do 2001.

JOSE LUIS SALAZAR LOPEZ
Director de Nuevas Creaciones (C)

El anterior requerimiento fue notificado por fijaciOn en lista, do fecha

2011

CONCEPTO TECNICO EXAMINADOR TECNICO
No.418 COdigo No. 202073

. Exp. 2007 70604